LOS ANGELES, CA – February 15, 2012– Ritter Pharmaceuticals, Inc. has announced today that the abstract summarizing results from its Phase 2 study of RP-G28, a first-in-class treatment for lactose intolerance, was chosen for oral presentation at the annual international Digestive Disease Week (DDW) 2012®, considered the largest meeting in the world for physicians and researchers in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
Dennis Savaiano, Ph.D., chairman of Ritter’s Medical Advisory Board and Professor of Nutrition Science at Purdue University, will make the presentation in San Diego, California on Tuesday, May 22 at 11:15 a.m. Pacific Time.
The DDW presentation describes the company’s recently announced Phase 2 study results, which demonstrate that treatment with RP‑G28 improves digestive symptoms associated with lactose intolerance and also reduces breath hydrogen production (a commonly used diagnostic test for lactose maldigestion). These Phase 2 data provide evidence to support the proof of concept for RP-G28 as a treatment for the symptoms associated with lactose intolerance.
This study marks a major milestone in lactose intolerance research as it represents the first controlled Phase 2 study for a prescription drug candidate for patients with lactose intolerance.
“Lactose intolerance is a very common condition representing a large unmet medical need,” said Andrew Ritter, President and CEO. “We are pleased to have the opportunity to share our Phase 2 results with the gastroenterology community at DDW 2012 and enthusiastic that our results further our development of this new therapy.”
RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance. RP‐G28 is an orally administered, proprietary oligosaccharide intended to alleviate the symptoms of lactose intolerance on a long-term basis and possibly impact the natural course of the disease.
About Lactose Intolerance
Lactose intolerance is a common gastrointestinal disease affecting nearly 60 million Americans and 2 out of 3 people worldwide. People with lactose intolerance have insufficient lactase, the enzyme lining the small bowel and responsible for breaking down lactose (“milk sugar”). The result is one or more gastrointestinal symptoms; including abdominal pain, cramps, bloating, gas, and/or diarrhea following the ingestion of lactose-containing foods.
About Ritter Pharmaceuticals, Inc.
Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Ritter is rapidly establishing itself as a world’s leader in lactose intolerance research. For additional information, please visit www.RitterPharma.com .
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of Ritter’s drug candidate, RP-G28, and RP-G28’s potential to treat the symptoms associated with lactose intolerance. Words such as “intended”, “potential” and similar words and expressions identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Ritter that any of its plans will be achieved. Future results can be affected by inaccurate assumptions and by known or unknown risks and uncertainties. For example, statements relating to Ritter’s ongoing clinical trials may turn out to be wrong because, among other things, Ritter’s product candidates may prove to be ineffective and planned studies could be delayed as a result of actions by third parties upon whom Ritter relies or Ritter’s own lack of financial resources. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Ritter undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.